Amgen Acquires DeCode for $415M
The target focuses on the link between genomes and disease susceptibility
Amgen (Nasdaq: AMGN) will acquire DeCode Genetics for $415 million.
DeCode, headquartered in Reykjavik, Iceland, is a human genetics research company that focuses on the link between genomes and disease susceptibility. The company was founded in 1996 and has discovered risk factors for dozens of diseases.
This year, the company published three studies on Alzheimer’s, the importance of a father’s age linked to disease risk and thyroid cancer risk.
Amgen is a Thousand Oaks, Calif.-based biotechnology company that develops medications for cancer, kidney disease, rheumatoid arthritis, bone disease and other illnesses.
For more coverage on Amgen and the pharmaceutical sector, read Mergers & Acquisitions’ “Dealmaker of the Year” story highlighting the accomplishments of Roger Perlmutter, Amgen's executive vice president, as well as "The Buyside: Big- and Mid- Market Pharma Grabs Spotlight."
For more information on related topics, visit the following: